Shares in biotech Pharmaxis have been placed in a two-day trading halt ahead of the decision by the expert advisory panel to the US FDA on whether to accept its Bronchitol drug.
Shares in biotech Pharmaxis have been placed in a two-day trading halt ahead of the decision by the expert advisory panel to the U.S. Food and Drug Administration on whether to accept Bronchitol for the treatment of cystic fibrosis.
Pulmonary-Allergy Drug Advisory Committee or “PADAC" review meeting is being held on Wednesday 30 January 2013 (US time), as flagged last week by the company.
